<DOC>
	<DOC>NCT00907894</DOC>
	<brief_summary>This is a Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of LDT600 in pediatric and adolescent patients with chronic hepatitis B infection.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Children and adolescents patients HBsAg seropositive Exclusion criteria: Decompensated liver disease (ChildTurcottePugh (CTP) Scoreâ‰¥7, Class B and C) Prior antiHBV therapy within 30 days of study drug dosing. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic hepatitis B,</keyword>
	<keyword>telbivudine,</keyword>
	<keyword>pharmacokinetics,</keyword>
	<keyword>safety,</keyword>
	<keyword>tolerability,</keyword>
	<keyword>pediatric</keyword>
</DOC>